Risk of Merkel Cell Carcinoma Progression After Treatment Discontinuation in Patients With an Objective Response to Anti-PD-(L)1 Immunotherapy
Studysummary In this retrospective study of patients with advanced Merkel cell carcinoma responding to immunotherapy, those treated for 18 months or longer showed better progression-free outcomes compared to shorter treatment durations, indicating potential benefits of extended therapy duration.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jidonline.org →